Non-Small Cell Lung Cancer - Localized and Unresectable

Correlatives

No Trials Currently Available

Inoperable Stage I/II

IRB#20077
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

IRB#19566
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NSCLC (LUNG-MAP SUB-STUDY)

IRB#20077
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Inoperable Stage IIA/B

IRB#19566
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent NSCLC (LUNG-MAP SUB-STUDY)

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php